Ob/Gyn Medical News about Estrogens

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004
The Breast Journal, 11/03/09

Parise CA et al. – The authors recommend reporting breast cancer as an ER/PR/HER2 subtype and precisely documenting demographic and tumor characteristics.

Exclusive Author Commentary
Carol A. Parise, 11/03/09

The ER/PR/HER2 subtypes in conjunction with appropriate immunhistochemical testing is a good surrogate for the molecular classification of breast cancer. This "poor man's" substitute for the molecular classification may also save healthcare dollars, an important consideration in today's economy.

<< Previous
Quantitative Assessment of Radiation-Induced Fibrosis of the...

Next >>
An open trial with cognitive behavioral therapy for blood- and...